Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label, Dose Finding Study of CC-95251 Alone and in Combination With Antineoplastic Agents in Subjects With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Next Previous
Trial Profile

A Phase 1, Open-label, Dose Finding Study of CC-95251 Alone and in Combination With Antineoplastic Agents in Subjects With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anzurstobart (Primary) ; Azacitidine (Primary) ; Venetoclax (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 19 Sep 2024 Status changed from active, no longer recruiting to completed.
  • 01 Apr 2024 Status changed from recruiting to active, no longer recruiting.
  • 07 Aug 2023 Number of treatment arms have been increased from 2 to 3 by the addition of Experimental: CC-95251 + azacitidine + venetoclax arm. Treatment naive Acute myeloid leukemia is added to inclusion in Part D and Venetoclax added as a study drug. Planned patient enrollment is increased.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top